There are currently 189 clinical trials in Sarasota, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Sarasota Memorial Hospital, Florida Cancer Specialists, GSK Investigational Site and Sarasota Retina Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT06322693
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: GSK Investigational Site, Sarasota, Florida
Conditions: Neoplasms
Register for Updates
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
NCT04770870
Recruiting
The H3 TAR Prosthesis was approved by FDA (P160036) on June 4, 2019. Continued approval of the premarket approval application (PMA) is contingent upon the submission of periodic reports (Annual Report), required under 21 CFR 814.84. In order to provide continued reasonable assurance of the safety and effectiveness of the PMA device, data from this post-approval study must be submitted to FDA in a PMA Post-Approval Study Report per the requirements set forth in the approval.
Gender:
All
Ages:
21 years and above
Trial Updated:
03/07/2024
Locations: Florida Orthopedic Foot & Ankle Center, Sarasota, Florida
Conditions: Osteoarthritis Ankle, Post-Traumatic Osteoarthritis of Ankle, Osteoarthritis of Ankle Secondary to Inflammatory Arthritis (Disorder)
Register for Updates
First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
NCT05527184
Recruiting
IMGN151-1001 is a Phase 1, first in human, open-label dose-escalation and expansion study in adult patients with recurrent endometrial cancer, recurrent, high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancers.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/27/2024
Locations: Florida Cancer Specialists, Sarasota, Florida
Conditions: Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
Register for Updates
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
NCT05405595
Recruiting
This is a Phase 1b/2, open-label, dose escalation study to evaluate the safety, tolerability, PK, and immunogenicity of ADG126-pembrolizumab combination regimens in patients with advanced/metastatic solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2024
Locations: Florida cancer specialist, Sarasota, Florida
Conditions: Advanced/Metastatic Solid Tumors
Register for Updates
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
NCT05785741
Recruiting
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/21/2024
Locations: Florida Cancer Specialists, Sarasota, Florida
Conditions: Advanced Solid Tumor
Register for Updates
Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation
NCT04088071
Recruiting
The primary purpose of this registry is to obtain real-world clinical experience of Paroxysmal (PAF) and Persistent (PsAF) Atrial Fibrillation ablation radiofrequency (RF) technologies. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long-term, effectiveness of catheter ablation with novel RF technologies in PAF and PsAF patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: Sarasota Memorial Hospital, Sarasota, Florida
Conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Register for Updates
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NCT05215574
Recruiting
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
02/12/2024
Locations: NGM Clinical Study Site, Sarasota, Florida
Conditions: Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Endocervical Cancer, Squamous Cell Carcinoma of Head and Neck, Bladder Urothelial Cancer, Colorectal Carcinoma, Esophageal Cancer, Ovarian Cancer, Renal Cell Carcinoma, Prostate Cancer, Melanoma, Mesothelioma, Cholangiocarcinoma
Register for Updates
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
NCT04354246
Recruiting
Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/10/2024
Locations: Florida Cancer Specialists, Sarasota, Florida
Conditions: Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC
Register for Updates
US Post-Market Surveillance Study of the Surfacer System
NCT05050799
Recruiting
Single arm, observational, multi-center, consecutively enrolling, post-market surveillance study. Treating patients in need of central venous access who have upper body venous occlusions or other conditions that preclude central venous access by conventional methods, and who meet the requirements described in the device labeling.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/07/2024
Locations: Sarasota Memorial Health Care System, Sarasota, Florida
Conditions: Venous Disease
Register for Updates
RESPONDER-HF Trial
NCT05425459
Recruiting
Multicenter, Prospective, Randomized, Sham Controlled, Double Blinded Clinical Trial, with; 1:1 randomization
Gender:
All
Ages:
40 years and above
Trial Updated:
02/05/2024
Locations: Sarasota Memorial Hospital (Intercoastal Medical Group), Sarasota, Florida
Conditions: Heart Failure, Heart Failure, Diastolic
Register for Updates
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer
NCT05654532
Recruiting
This clinical trial is evaluating a drug called AC699 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to: Identify the recommended dose of AC699 that can be given safely to participants Evaluate the safety profile of AC699 Evaluate the pharmacokinetics of AC699 Evaluate the effectiveness of AC699
Gender:
All
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Site 02, Sarasota, Florida
Conditions: Breast Cancer
Register for Updates
A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee
NCT06000410
Recruiting
This study is being conducted to evaluate the efficacy and safety of ASA compared to placebo in the management of osteoarthritis (OA) symptoms of the knee.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: Gulfcoast Research Institute, Sarasota, Florida
Conditions: Knee Osteoarthritis
Register for Updates